A randomized double-blind placebo-controlled clinical trial of nitazoxanide for treatment of mild or moderate COVID-19
Open Access
- 28 February 2022
- journal article
- research article
- Published by Elsevier in eClinicalMedicine
- Vol. 45, 101310
Abstract
No abstract availableKeywords
All Related Versions
This publication has 23 references indexed in Scilit:
- Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitroCell Research, 2020
- Nitazoxanide inhibits paramyxovirus replication by targeting the Fusion protein folding: role of glycoprotein-specific thiol oxidoreductase ERp57Scientific Reports, 2018
- Performance of the inFLUenza Patient-Reported Outcome (FLU-PRO) diary in patients with influenza-like illness (ILI)PLOS ONE, 2018
- Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirusJournal of Infection and Public Health, 2016
- A screen of the NIH Clinical Collection small molecule library identifies potential anti-coronavirus drugsAntiviral Research, 2015
- Nitazoxanide: A first-in-class broad-spectrum antiviral agentAntiviral Research, 2014
- Effect of nitazoxanide in adults and adolescents with acute uncomplicated influenza: a double-blind, randomised, placebo-controlled, phase 2b/3 trialThe Lancet Infectious Diseases, 2014
- Nitazoxanide suppresses IL-6 production in LPS-stimulated mouse macrophages and TG-injected miceInternational Immunopharmacology, 2012
- Thiazolides, a New Class of Anti-influenza Molecules Targeting Viral Hemagglutinin at the Post-translational LevelJournal of Biological Chemistry, 2009
- Potential for Hepatitis C Virus Resistance to Nitazoxanide or TizoxanideAntimicrobial Agents and Chemotherapy, 2008